Galectin Therapeutics financials
$3.91−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.0M | -$4.1M | -$3.4M | -$4.2M | -$4.6M | -$7.9M | -$12.4M | -$9.1M | -$11.3M | -$9.6M | -$9.6M | -$9.2M |
| Net income | -$9.2M | -$5.1M | -$5.6M | -$8.2M | -$7.6M | -$9.6M | -$12.0M | -$11.2M | -$12.4M | -$11.5M | -$10.1M | -$14.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.14 | $-0.08 | $-0.09 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.18 | $-0.20 | $-0.19 | $-0.16 | $-0.24 |
| EBITDA | -$4.0M | -$4.1M | -$3.4M | -$4.2M | -$4.6M | -$7.9M | -$12.4M | -$9.1M | -$11.3M | -$9.6M | -$9.6M | -$9.2M |
| Operating cash flow | -$2.4M | -$3.9M | -$6.0M | -$3.5M | -$6.6M | -$7.7M | -$12.8M | -$8.5M | -$8.3M | -$12.1M | -$4.7M | -$7.6M |
| Free cash flow | -$2.4M | -$3.9M | -$6.0M | -$3.5M | -$6.6M | -$7.7M | -$12.8M | -$8.5M | -$8.3M | -$12.1M | -$4.7M | -$7.6M |
| Diluted shares | 65.9M | 65.8M | 64.8M | 64.2M | 63.4M | 63.2M | 62.7M | 62.3M | 62.2M | 62.0M | 61.9M | 59.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.3M | $14.1M | $17.7M | $11.5M | $13.8M | $7.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $33.0M | $32.9M | $32.7M | $122.3M | $32.3M | $32.1M |
| Total assets | $14.8M | $15.8M | $19.5M | $12.9M | $15.6M | $9.5M |
| Total liabilities | $151.7M | $146.0M | $145.7M | $136.4M | $132.8M | $121.8M |
| Shareholders' equity | -$138.6M | -$132.0M | -$127.9M | -$125.3M | -$118.9M | -$114.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology